Skip to content
10-Q

Quarterly Report

Prime Medicine, Inc. PRME

0001628280-26-031726

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 180.62M sh
Shares Diluted Q1 2026 · Mar 31, 2026 177.1M sh
Shares Diluted Q1 2026 · Mar 31, 2025 130.88M sh
Capex Q1 2026 · Mar 31, 2026 $214K
Capex Q1 2026 · Mar 31, 2025 $2.42M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$42.71M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$48.86M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $64.11M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $63.03M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $91.88M
Stockholders Equity Q1 2026 · Mar 31, 2026 $76.7M
Stockholders Equity Q1 2026 · Dec 31, 2025 $120.87M
Stockholders Equity Q1 2026 · Mar 31, 2025 $106.92M
Stockholders Equity Q1 2026 · Dec 31, 2024 $153.15M
Current Liabilities Q1 2026 · Mar 31, 2026 $36.29M
Current Liabilities Q1 2026 · Dec 31, 2025 $37.45M
Total Liabilities Q1 2026 · Mar 31, 2026 $218.03M
Total Liabilities Q1 2026 · Dec 31, 2025 $221.87M
Current Assets Q1 2026 · Mar 31, 2026 $137.89M
Current Assets Q1 2026 · Dec 31, 2025 $181.29M
Total Assets Q1 2026 · Mar 31, 2026 $294.73M
Total Assets Q1 2026 · Dec 31, 2025 $342.73M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.28
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.40
Eps Basic Q1 2026 · Mar 31, 2026 −$0.28
Eps Basic Q1 2026 · Mar 31, 2025 −$0.40
Sga Expense Q1 2026 · Mar 31, 2026 $17.41M
Sga Expense Q1 2026 · Mar 31, 2025 $13.28M
Rd Expense Q1 2026 · Mar 31, 2026 $34.11M
Rd Expense Q1 2026 · Mar 31, 2025 $40.56M
Net Income Q1 2026 · Mar 31, 2026 −$49.12M
Net Income Q1 2026 · Mar 31, 2025 −$51.89M
Operating Income Q1 2026 · Mar 31, 2026 −$50.65M
Operating Income Q1 2026 · Mar 31, 2025 −$52.39M